{% extends "layout.html" %}

{% block content %}
<div class="container" >
  <h3>EXPLANATION OF THE SYSTEM TESTS</h3>

  The following table outlines in detail what is being assessed in each of the systemâ€™s tests.
  <table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=460
 style='width:459.75pt;margin-left:4.65pt;border-collapse:collapse;mso-yfti-tbllook:
 1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt'>
 <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;height:26.45pt'>
  <td width=140 style='width:140.25pt;border:solid windowtext 1.0pt;mso-border-alt:
  solid windowtext 1.0pt;mso-border-bottom-alt:solid windowtext .5pt;
  background:#B7DEE8;padding:0cm 5.4pt 0cm 5.4pt;height:26.45pt'>
  <p class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
  text-align:center;line-height:normal'><b style='mso-bidi-font-weight:normal'><span
  lang=EN-GB style='font-size:12.0pt;mso-ascii-font-family:
  Calibri;mso-fareast-font-family:"Times New Roman";mso-hansi-font-family:Calibri;
  mso-bidi-font-family:"Times New Roman";color:black;mso-fareast-language:EN-GB;
  mso-bidi-font-style:italic'>TEST<o:p></o:p></span></b></p>
  </td>
  <td width=320 style='width:319.5pt;border:solid windowtext 1.0pt;border-left:
  none;mso-border-top-alt:solid windowtext 1.0pt;mso-border-bottom-alt:solid windowtext .5pt;
  mso-border-right-alt:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt;
  height:26.45pt'>
  <p class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
  text-align:center;line-height:normal'><b style='mso-bidi-font-weight:normal'><span
  lang=EN-GB style='font-size:12.0pt;mso-ascii-font-family:
  Calibri;mso-fareast-font-family:"Times New Roman";mso-hansi-font-family:Calibri;
  mso-bidi-font-family:"Times New Roman";color:black;mso-fareast-language:EN-GB'>EXPLANATION<o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1;height:25.55pt'>
  <td width=140 valign=top style='width:140.25pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext 1.0pt;mso-border-alt:
  solid windowtext 1.0pt;mso-border-bottom-alt:solid windowtext .5pt;
  background:#B7DEE8;padding:0cm 5.4pt 0cm 5.4pt;height:25.55pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><i><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'>Did the facility submit an order?<o:p></o:p></span></i></p>
  </td>
  <td width=320 valign=top style='width:319.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:25.55pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'>Reports if the facility has submitted
  an order or not during a given cycle<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2;height:40.0pt'>
  <td width=140 valign=top style='width:140.25pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext 1.0pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext 1.0pt;background:
  #B7DEE8;padding:0cm 5.4pt 0cm 5.4pt;height:40.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><i><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'>Did the facility submit a web or
  paper-based order?<o:p></o:p></span></i></p>
  </td>
  <td width=320 valign=top style='width:319.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:40.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'>Reports if the facility has submitted
  an order through WAOS or a paper-based submission (or not at all, where the
  result is &quot;n/a&quot;)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3;height:107.5pt'>
  <td width=140 valign=top style='width:140.25pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext 1.0pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext 1.0pt;background:
  #B7DEE8;padding:0cm 5.4pt 0cm 5.4pt;height:107.5pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><i><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'>GUIDELINE ADHERENCE (Adult 1L):
  Estimated new patients on TDF-based formulations are 80%+ of total?<o:p></o:p></span></i></p>
  </td>
  <td width=320 valign=top style='width:319.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:107.5pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'>Tests is the facility is adhering to
  national guidelines for Adult 1st Line therapy.<br>
  <br>
  This is done by testing if the volume of estimated new ART patients on <u>Adult
  TDF-based formulations</u> (i.e. TDF/3TC/EFV 300/300/600mg and TDF/3TC
  300/300mg) represent <b>at least 80%</b> of the total of those on TDF-based
  and AZT-based formulations (Adult AZT-based formulations are AZT/3TC/NVP
  300/150/200mg and AZT/3TC 300/150mg)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4;height:94.0pt'>
  <td width=140 valign=top style='width:140.25pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext 1.0pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext 1.0pt;background:
  #B7DEE8;padding:0cm 5.4pt 0cm 5.4pt;height:94.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><i><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'>GUIDELINE ADHERENCE (Adult 2L):
  Estimated new patients on ATV/r-based formulations are 73%+ of total?<o:p></o:p></span></i></p>
  </td>
  <td width=320 valign=top style='width:319.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:94.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'>Tests is the facility is adhering to
  national guidelines for Adult 2nd Line therapy<br>
  <br>
  This is done by testing if the volume of estimated new ART patients on <u>Adult
  ATV/r-based formulations</u> (i.e. ATV/r 300/100mg) represent <b>at least 73%</b>
  of the total of those on ATV/r-based and LPV/r-based formulations (Adult
  LPV/r-based formulations are LPV/r 200/50mg)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5;height:107.5pt'>
  <td width=140 valign=top style='width:140.25pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext 1.0pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext 1.0pt;background:
  #B7DEE8;padding:0cm 5.4pt 0cm 5.4pt;height:107.5pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><i><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'>GUIDELINE ADHERENCE (Paediatric 1L):
  Estimated new patients on ABC-based formulations are 80%+ of total?<o:p></o:p></span></i></p>
  </td>
  <td width=320 valign=top style='width:319.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:107.5pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'>Tests is the facility is adhering to
  national guidelines for Paediatric 1st Line therapy<br>
  <br>
  This is done by testing if the volume of estimated new ART patients on <u>Paediatric
  ABC-based formulations</u> (i.e. ABC/3TC 60/30mg) represent <b>at least 80%</b>
  of the total of those on ABC-based and AZT-based formulations (Paediatric
  AZT-based formulations are AZT/3TC/NVP 60/30/50mg and AZT/3TC 60/30mg)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6;height:30.0pt'>
  <td width=140 valign=top style='width:140.25pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext 1.0pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext 1.0pt;background:
  #B7DEE8;padding:0cm 5.4pt 0cm 5.4pt;height:30.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><i><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'>MULTIPLE ORDERS: Submitted more than
  one order?<o:p></o:p></span></i></p>
  </td>
  <td width=320 valign=top style='width:319.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:30.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'>Reports facilities that have
  submitted more than one order during a given cycle<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7;height:45.85pt'>
  <td width=140 valign=top style='width:140.25pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext 1.0pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext 1.0pt;background:
  #B7DEE8;padding:0cm 5.4pt 0cm 5.4pt;height:45.85pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><i><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'>NO BLANKS: Order form free of blanks?<o:p></o:p></span></i></p>
  </td>
  <td width=320 valign=top style='width:319.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:45.85pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'>Tests if the facility has submitted a
  complete order form or has left blanks in any data fields where a number
  (either zero or otherwise) should have been input<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8;height:98.05pt'>
  <td width=140 valign=top style='width:140.25pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext 1.0pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext 1.0pt;background:
  #B7DEE8;padding:0cm 5.4pt 0cm 5.4pt;height:98.05pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><i><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'>NO NEGATIVES: Order free of negative
  inputs?<o:p></o:p></span></i></p>
  </td>
  <td width=320 valign=top style='width:319.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:98.05pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><i><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'>This test is carried out for the
  system's three Sample Formulations: 1) Adult TDF/3TC/EFV (300/300/600mg), 2)
  Paediatric ABC/3TC (60/30mg), and 3) Paediatric EFV(200mg)</span></i><span
  lang=EN-GB style='font-size:10.0pt;mso-ascii-font-family:
  Calibri;mso-fareast-font-family:"Times New Roman";mso-hansi-font-family:Calibri;
  mso-bidi-font-family:"Times New Roman";color:black;mso-fareast-language:EN-GB'><br>
  <br>
  Tests if the facility has input a negative number into any of four key data
  fields (Opening Balance, ART Consumption, Closing Balance and Estimated New
  ART Patients) where a positive number or zero should be<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9;height:319.0pt'>
  <td width=140 valign=top style='width:140.25pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext 1.0pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext 1.0pt;background:
  #B7DEE8;padding:0cm 5.4pt 0cm 5.4pt;height:319.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><i><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB';>VOLUME TALLY: Consumption and patient
  volumes within 30%?<o:p></o:p></span></i></p>
  </td>
  <td width=320 valign=top style='width:319.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:319.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><i><span lang=EN-GB style='font-size:10.0pt;
  mso-fareast-language:EN-GB;color:black'>This test is carried out for the system's three
  Sample Formulations: 1) Adult TDF/3TC/EFV (300/300/600mg), 2) Paediatric
  ABC/3TC (60/30mg), and 3) Paediatric EFV(200mg)<br>
  </span></i><span lang=EN-GB style='font-size:10.0pt;
  mso-fareast-language:EN-GB;color:black'><br>
  Tests if the facility has reported corresponding Consumption volumes and
  Patient numbers that &quot;make sense&quot;, i.e. are within 30% of each
  other. The specific datapoints compared are:<br>
  <br>
  1) For Sample Formulation 1,<b> Adult TDF/3TC/EFV</b>: Compares bimonthly
  Consumption volumes of formulation <u>Tenofovir/Lamivudine/Efavirenz
  (TDF/3TC/EFV) 300mg/300mg/600mg[Pack 30]</u> (converted into an estimated
  Patients figure by dividing by 2.0) with Patient Numbers for regimens <u>TDF/3TC/EFV
  (ADULT)</u> and <u>TDF/3TC/EFV (PMTCT)</u><br style='mso-special-character:
  line-break'>
  <![if !supportLineBreakNewLine]><br style='mso-special-character:line-break'>
  <![endif]><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-GB style='font-size:10.0pt;
  mso-fareast-language:EN-GB;color:black'>2) For Sample Formulation 2, <b>Paediatric
  ABC/3TC</b>: Compares bimonthly Consumption volumes of formulation <u>Abacavir/Lamivudine
  (ABC/3TC) 60mg/30mg [Pack 60]</u> (converted into an estimated Patients
  figure by dividing by 4.6) with Patient Numbers for regimens <u>ABC/3TC/EFV
  (PAED)</u>, <u>ABC/3TC/NVP (PAED)</u> and <u>ABC/3TC/LPV/r (PAED)<br
  style='mso-special-character:line-break'>
  <![if !supportLineBreakNewLine]><br style='mso-special-character:line-break'>
  <![endif]></u><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-GB style='font-size:10.0pt;
  mso-fareast-language:EN-GB;color:black'>3) For Sample Formulation 3, <b>Paediatric EFV</b>:
  Compares bimonthly Consumption volumes of formulation <u>Efavirenz (EFV)
  200mg [Pack 90]</u> (converted into an estimated Patients figure by dividing
  by 1.0) with Patient Numbers for regimens <u>ABC/3TC/EFV (PAED)</u> and <u>AZT/3TC/EFV
  (PAED)</u><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10;height:117.4pt'>
  <td width=140 valign=top style='width:140.25pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext 1.0pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext 1.0pt;background:
  #B7DEE8;padding:0cm 5.4pt 0cm 5.4pt;height:117.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><i><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'>NON-REPEATING: Order changes in consecutive
  cycles?<o:p></o:p></span></i></p>
  </td>
  <td width=320 valign=top style='width:319.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:117.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><i><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'>This test is carried out for the
  system's three Sample Formulations: 1) Adult TDF/3TC/EFV (300/300/600mg), 2)
  Paediatric ABC/3TC (60/30mg), and 3) Paediatric EFV(200mg)</span></i><span
  lang=EN-GB style='font-size:10.0pt;mso-ascii-font-family:
  Calibri;mso-fareast-font-family:"Times New Roman";mso-hansi-font-family:Calibri;
  mso-bidi-font-family:"Times New Roman";color:black;mso-fareast-language:EN-GB'><br>
  <br>
  Tests if the facility has submitted the same order in consecutive cycles.
  This is done by comparing certain key datapoints (Opening Balance, ART
  Consumption, Closing Balance and Estimated New ART Patients) from a given
  cycle with the same datapoints reported in the previous cycle<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:11;height:94.45pt'>
  <td width=140 valign=top style='width:140.25pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext 1.0pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext 1.0pt;background:
  #B7DEE8;padding:0cm 5.4pt 0cm 5.4pt;height:94.45pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><i><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'>OPENING = CLOSING: Opening<span
  style='mso-spacerun:yes'>&nbsp; </span>balance = Closing balance from
  previous cycle?<o:p></o:p></span></i></p>
  </td>
  <td width=320 valign=top style='width:319.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:94.45pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><i><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'>This test is carried out for the
  system's three Sample Formulations: 1) Adult TDF/3TC/EFV (300/300/600mg), 2)
  Paediatric ABC/3TC (60/30mg), and 3) Paediatric EFV(200mg)</span></i><span
  lang=EN-GB style='font-size:10.0pt;mso-ascii-font-family:
  Calibri;mso-fareast-font-family:"Times New Roman";mso-hansi-font-family:Calibri;
  mso-bidi-font-family:"Times New Roman";color:black;mso-fareast-language:EN-GB'><br>
  <br>
  Tests if the &quot;Opening Balance&quot; reported by the facility in one
  cycle is the same as the &quot;Closing Balance&quot; result of the previous
  cycle<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:12;height:242.5pt'>
  <td width=140 valign=top style='width:140.25pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext 1.0pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext 1.0pt;background:
  #B7DEE8;padding:0cm 5.4pt 0cm 5.4pt;height:242.5pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><i><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'>STABLE CONSUMPTION: Consumption
  changes by less than 50% vs. previous cycle?<o:p></o:p></span></i></p>
  </td>
  <td width=320 valign=top style='width:319.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:242.5pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><i><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'>This test is carried out for the
  system's three Sample Formulations: 1) Adult TDF/3TC/EFV (300/300/600mg), 2)
  Paediatric ABC/3TC (60/30mg), and 3) Paediatric EFV(200mg)</span></i><span
  lang=EN-GB style='font-size:10.0pt;mso-ascii-font-family:
  Calibri;mso-fareast-font-family:"Times New Roman";mso-hansi-font-family:Calibri;
  mso-bidi-font-family:"Times New Roman";color:black;mso-fareast-language:EN-GB'><br>
  <br>
  Tests if the facility's total Consumption volume (i.e. ART Consumption +
  PMTCT Consumption) in a given cycle is stable relative to that of the
  previous cycle, with stability defined as a change of less than 50%. This
  test is run for the system's three Sample Formulations but excludes
  facilities that are considered &quot;low volume&quot;, according to the following
  rules:<br>
  <br>
  1) For Sample Formulation 1, <b>Adult TDF/3TC/EFV:</b> Total consumption in
  either cycle must be at least 20 packs<o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'><br>
  2) For Sample Formulation 2, <b>Paediatric ABC/3TC: </b>Total consumption in
  either cycle must be at least 10 packs<br style='mso-special-character:line-break'>
  <![if !supportLineBreakNewLine]><br style='mso-special-character:line-break'>
  <![endif]><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'>3) For Sample Formulation 3, <b>Paediatric
  EFV: </b>Total consumption in either cycle must be at least 10 packs<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:13;height:121.45pt'>
  <td width=140 valign=top style='width:140.25pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext 1.0pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext 1.0pt;background:
  #B7DEE8;padding:0cm 5.4pt 0cm 5.4pt;height:121.45pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><i><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'>WAREHOUSE FULFILMENT: Volume
  delivered = volume ordered in previous cycle?<o:p></o:p></span></i></p>
  </td>
  <td width=320 valign=top style='width:319.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:121.45pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><i><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'>This test is carried out for the
  system's three Sample Formulations: 1) Adult TDF/3TC/EFV (300/300/600mg), 2)
  Paediatric ABC/3TC (60/30mg), and 3) Paediatric EFV(200mg)</span></i><span
  lang=EN-GB style='font-size:10.0pt;mso-ascii-font-family:
  Calibri;mso-fareast-font-family:"Times New Roman";mso-hansi-font-family:Calibri;
  mso-bidi-font-family:"Times New Roman";color:black;mso-fareast-language:EN-GB'><br>
  <br>
  Tests if the &quot;Quantity Received&quot; reported by the facility in one
  cycle is the same as the &quot;Packs Ordered&quot; result of the previous
  cycle.<br>
  This test can therefore reflect more than just the facility's ability to
  input correct figures as per what has been delivered. It also tests warehouse
  ability to correctly deliver what has been requested<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:14;height:247.45pt'>
  <td width=140 valign=top style='width:140.25pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext 1.0pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext 1.0pt;background:
  #B7DEE8;padding:0cm 5.4pt 0cm 5.4pt;height:247.45pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><i><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'>STABLE PATIENTS: Patient volumes
  change by less than 50% vs. previous cycle?<o:p></o:p></span></i></p>
  </td>
  <td width=320 valign=top style='width:319.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:247.45pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><i><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'>This test is carried out for the
  system's three Sample Formulations: 1) Adult TDF/3TC/EFV (300/300/600mg), 2)
  Paediatric ABC/3TC (60/30mg), and 3) Paediatric EFV(200mg)</span></i><span
  lang=EN-GB style='font-size:10.0pt;mso-ascii-font-family:
  Calibri;mso-fareast-font-family:"Times New Roman";mso-hansi-font-family:Calibri;
  mso-bidi-font-family:"Times New Roman";color:black;mso-fareast-language:EN-GB'><br>
  <br>
  Tests if the facility's total Patient number (i.e. Existing + New patients)
  in a given cycle is stable relative to that of the previous cycle, with
  stability defined as a change of less than 50%. This test is run for the
  system's three Sample Formulations but excludes facilities that are
  considered &quot;low volume&quot;, according to the following rules:<br>
  <br>
  1) For Sample Formulation 1, <b>Adult TDF/3TC/EFV:</b> Total patients in
  either cycle <u>on regimen TDF/3TC/EFV</u> must be at least 10<o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'><br>
  2) For Sample Formulation 2, <b>Paediatric ABC/3TC: </b>Total paediatric
  patients in either cycle <u>on regimens ABC/3TC/EFV and ABC/3TC/NVP</u> must
  be at least 5<o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'><br>
  3) For Sample Formulation 3, <b>Efavirenz 200: </b>Total paediatric patients
  in either cycle <u>on regimens ABC/3TC/EFV and AZT/3TC/EFV</u> must be at
  least 5<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:15;height:189.4pt'>
  <td width=140 valign=top style='width:140.25pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext 1.0pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext 1.0pt;background:
  #B7DEE8;padding:0cm 5.4pt 0cm 5.4pt;height:189.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><i><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'>NRTI and NNRTI/PI patient volumes
  (ADULT - CURRENT): Differ by &lt;30%?<o:p></o:p></span></i></p>
  </td>
  <td width=320 valign=top style='width:319.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:189.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'>Tests if the current patient numbers
  implied by facility's reported <b><u>Adult NRTI</u></b> consumption volumes
  are similar to those implied by the reported <b><u>Adult NNRTI/PI</u></b>
  consumption volumes<br>
  <br>
  This is done by taking total consumption volumes (ART and PMTCT) for each of
  the formulations below, converting to patient numbers (by dividing through by
  2.0 for all formulations), summing the totals for both sets of formulations
  (NRTI and NNRTI/PI) separately, and finally testing if the two resulting
  figures are within 30% of each other.<br>
  <br>
  NRTI formulations: TDF/3TC 300/300mg, AZT/3TC 300/150mg, ABC/3TC 600/300mg<br>
  NNRTI/PI formulations: NVP 200mg, EFV 600mg, ATV/r 300/100mg, LPV/r 200/50mg<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:16;height:188.5pt'>
  <td width=140 valign=top style='width:140.25pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext 1.0pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext 1.0pt;background:
  #B7DEE8;padding:0cm 5.4pt 0cm 5.4pt;height:188.5pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><i><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'>NRTI and NNRTI/PI patient volumes
  (PAED - CURRENT): Differ by &lt;30%?<o:p></o:p></span></i></p>
  </td>
  <td width=320 valign=top style='width:319.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:188.5pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'>Tests if the current patient numbers
  implied by facility's reported <b><u>Paediatric NRTI</u></b> consumption
  volumes are similar to those implied by the reported <b><u>Paediatric
  NNRTI/PI</u></b> consumption volumes<br>
  <br>
  This is done by taking total consumption volumes (ART and PMTCT) for each of
  the formulations below, converting to patient numbers (by dividing through by
  4.6 for all formulations apart from EFV 200mg which you divide through by
  1.0), summing the totals for both sets of formulations (NRTI and NNRTI/PI)
  separately, and finally testing if the two resulting figures are within 30%
  of each other<br>
  <br>
  NRTI formulations: AZT/3TC 60/30mg, ABC/3TC 60/30mg<br>
  NNRTI/PI formulations: NVP 50mg, EFV 200mg, LPV/r 100/25mg, LPV/r 80/20mg<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:17;height:152.5pt'>
  <td width=140 valign=top style='width:140.25pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext 1.0pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext 1.0pt;background:
  #B7DEE8;padding:0cm 5.4pt 0cm 5.4pt;height:152.5pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><i><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'>NRTI and NNRTI/PI patient volumes
  (ADULT - ESTIMATED NEW): Differ by &lt;30%?<o:p></o:p></span></i></p>
  </td>
  <td width=320 valign=top style='width:319.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:152.5pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'>Tests if the facility's total
  estimated new patients for <b><u>Adult NRTI</u></b> formulations is similar
  to those for <b><u>Adult NNRTI/PI</u></b> formulations<br>
  <br>
  This is done by summing the estimated new patients (ART and pregnant women)
  for both sets of formulations (NRTI and NNRTI/PI) separately, and then
  testing if the two resulting figures are within 30% of each other<br>
  <br>
  NRTI formulations: TDF/3TC 300/300mg, AZT/3TC 300/150mg, ABC/3TC 600/300mg<br>
  NNRTI/PI formulations: NVP 200mg, EFV 600mg, ATV/r 300/100mg, LPV/r 200/50mg<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:18;mso-yfti-lastrow:yes;height:135.4pt'>
  <td width=140 valign=top style='width:140.25pt;border:solid windowtext 1.0pt;
  border-top:none;background:#B7DEE8;padding:0cm 5.4pt 0cm 5.4pt;height:135.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><i><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'>NRTI and NNRTI/PI patient volumes
  (PAED - ESTIMATED NEW): Differ by &lt;30%?<o:p></o:p></span></i></p>
  </td>
  <td width=320 valign=top style='width:319.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:135.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-GB style='font-size:10.0pt;
  color:black;mso-fareast-language:EN-GB'>Tests if the facility's total
  estimated new patients for <b><u>Paediatric NRTI</u></b> formulations is
  similar to those for <b><u>Paediatric NNRTI/PI</u></b> formulations<br>
  <br>
  This is done by summing the estimated new ART patients for both sets of
  formulations (NRTI and NNRTI/PI) separately, and then testing if the two
  resulting figures are within 30% of each other<br>
  <br>
  NRTI formulations: AZT/3TC 60/30mg, ABC/3TC 60/30mg<br>
  NNRTI/PI formulations: NVP 50mg, EFV 200mg, LPV/r 100/25mg, LPV/r 80/20mg<o:p></o:p></span></p>
  </td>
 </tr>
</table>

</div>
{% endblock content %}
